Sermorelin vs. Tesamorelin: Same Signal, Different Molecules

Both peptides tell your pituitary to make more of its own growth hormone. From there, they differ in length, in how long they survive in the body, in the evidence behind them, and in how hard they are to make well.

What they have in common

Your hypothalamus releases a 44-amino-acid peptide called growth hormone–releasing hormone (GHRH). It travels to the pituitary gland, binds the GHRH receptor, and triggers a pulse of growth hormone (GH). GH then drives the liver to produce IGF-1, which carries out many of GH’s effects on body composition and metabolism.

Sermorelin and tesamorelin are both versions of GHRH. Neither one is growth hormone. Each works upstream, asking the pituitary to release its own GH in pulses. That distinction matters: the body’s normal feedback controls, including somatostatin and IGF-1, stay in play, which is a different situation from injecting GH directly.

Where they differ: two molecules, side by side

The difference is easiest to see drawn out one amino acid at a time.

Sermorelin is the first 29 amino acids of human GHRH, the shortest piece that keeps the full activity of the natural hormone. Its front end is left as nature made it.

Tesamorelin keeps all 44 amino acids and adds one small but deliberate change: a trans-3-hexenoyl group, a six-carbon acid chain, attached to the first amino acid (tyrosine).

Why one small cap changes how the molecule behaves

Natural GHRH and sermorelin share a weak point. An enzyme in the blood called dipeptidyl peptidase-4 (DPP-4) clips off the first two amino acids, cutting between alanine-2 and aspartate-3. The shortened fragment no longer activates the receptor. This is one reason sermorelin’s half-life is measured in minutes.

The hexenoyl group on tesamorelin sits right at that site and blocks the enzyme. The result is a molecule that lasts longer in circulation and produces a stronger, more sustained GH and IGF-1 response per dose. The prescribing information for the FDA-approved tesamorelin product reports a half-life of roughly 26 to 38 minutes, compared with roughly 10 to 20 minutes reported for sermorelin.^1,10

Tesamorelin: what the trials show

Tesamorelin has one of the strongest clinical records of any peptide in this class, built on large, randomized, placebo-controlled trials.

• Visceral fat reduction. In the first Phase 3 trial, 412 adults with HIV-associated abdominal fat took tesamorelin or placebo daily for 26 weeks. Visceral fat, the deep fat packed around the abdominal organs, fell by about 15 percent on tesamorelin while it rose slightly on placebo.² A second Phase 3 trial confirmed the result, and a pooled analysis of more than 800 participants showed the same pattern.³
• Fat lost where it matters, with lean mass kept. The reduction was concentrated in visceral fat, with little change in the fat just under the skin, and lean body mass was maintained or increased. Waist size and patients’ own ratings of their belly appearance also improved.^2,3
• Better lipids. Triglycerides and the ratio of total to HDL cholesterol improved alongside the drop in visceral fat, and participants who lost the most visceral fat tended to see the largest metabolic benefits.^2,3
• Less liver fat. In randomized trials of people with HIV and excess liver fat, tesamorelin reduced liver fat compared with placebo, and the one-year trial also found less progression of liver fibrosis.^4,5
• Beyond HIV. In a 12-month randomized trial of adults with abdominal obesity and reduced growth hormone secretion, without HIV, tesamorelin lowered visceral fat and triglycerides and improved markers of cardiovascular risk.⁶ In a 20-week randomized trial in older adults, including some with mild cognitive impairment, it was associated with improved performance on tests of executive function.⁷

Sermorelin: what the research shows

Sermorelin’s appeal is that it works with your body’s own system. Growth hormone output declines steadily with age, and sermorelin asks the pituitary to raise it again in natural pulses, with the body’s feedback controls still in charge.

• Restores GH and IGF-1 in older adults. In older men, short courses of sermorelin raised GH and IGF-1 levels toward those typical of younger adults, showing that the aging pituitary can still respond when given the signal.⁹
• Body composition and metabolism. In a 12-week study of nightly sermorelin in men and women aged 55 and older, GH and IGF-1 rose in both groups. The men also showed an increase in lean body mass and improved insulin sensitivity, along with better reported well-being.⁸
• A physiologic approach. Because the pituitary still controls release, sermorelin produces pulses rather than the constant high levels that can come from injecting GH directly, and the body’s IGF-1 feedback keeps working as a brake.
• A long track record. Sermorelin was FDA-approved in the 1990s, under the brand name Geref, for children with growth hormone deficiency. The manufacturer later discontinued it, and the discontinuation is generally attributed to commercial reasons rather than safety.¹⁰
• Sleep and recovery. GHRH, the natural hormone sermorelin is based on, has been shown in sleep-lab studies to deepen slow-wave sleep. This is one reason sermorelin is usually dosed at bedtime, although its own effects on sleep have not been tested as rigorously.

Why tesamorelin is hard to make well

This is where a peptide’s chemistry turns into a real-world quality question. Peptides like these are built one amino acid at a time by solid-phase synthesis. Each coupling step is very efficient, but not perfect, and the losses compound.

• Length multiplies the problem. At 99 percent efficiency per step, 44 couplings leave only about 64 percent of chains at full, correct length before purification. Sermorelin’s 29 steps are more forgiving.
• The impurities look almost identical to the product. A chain missing a single amino acid out of 44 behaves very much like the real thing in HPLC, which makes these “deletion” impurities hard to separate and hard to detect without a well-developed method.
• Built-in weak spots. Both molecules contain methionine at position 27, which oxidizes easily, and asparagine at position 8, which can deamidate. Both reactions change the molecule and can happen during manufacturing, storage, or once the peptide is in solution.
• The cap has to be right, too. The hexenoyl group has to be attached completely, and its double bond has to stay in the correct position and trans geometry. Uncapped or isomerized material is a closely related impurity, and the uncapped form is exposed to exactly the enzyme the cap is meant to block.

For these reasons, the quality of a tesamorelin product depends on more than a single purity number. It also depends on formulation. These peptides have to be kept dissolved and stable in a vial that will be punctured again and again, which is why every AJ Peptide product is provided formulated in solution rather than as powder you mix yourself.

AJ Peptide is LegitScript certified.